The global next-generation multiple myeloma therapies market, valued at US$23.13 billion in 2024, is projected to reach US$37.07 billion by 2033 at a 5.4% CAGR. Explore drivers like accelerated FDA approvals (e.g., Lynozyfic), bispecific antibodies' rise, and CAR T-cell innovations amid precision diagnostics like MY-RADS MRI and liquid biopsies. https://finance.yahoo.com/news/next-generation-multiple-myeloma-therapies-112000005.html